PORTLAND, Ore., May 16, 2016 /PRNewswire/ -- AbSci announced
today the appointment of Daniel
Gold, Ph.D. to AbSci's Board of Directors. Dr. Gold has
served in senior management roles at several leading biotechnology
companies and currently serves as Vice President of Process
Sciences at BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN).
"Dr. Gold brings over 30 years of experience in the biotech
industry as both a scientist and executive. His vast technical
expertise in scaling up of industrial fermentation processes along
with his understanding of downstream process development will be
invaluable for us as we continue to develop our technology," said
Sean McClain, Founder and CEO of
AbSci. "We are honored to welcome his input and guidance in
advancing the commercialization of SoluPro™."
"I am very excited about the opportunity to join AbSci's Board
of Directors," said Dr. Gold. "The economical production of
complex biologicals remains an unmet need for the biotechnology
industry. AbSci's novel SoluPro™ technology provides a means
towards this industry-wide goal. I look forward to
participating in the development, implementation, and partnering of
this major scientific and engineering advancement.
Dr. Gold currently serves as VP of Process Sciences at BioMarin
Pharmaceuticals, where he oversees more than 100 employees and is
responsible for upstream, downstream, formulation, and analytical
development. Previously, he was CEO and President of Sutro
Biopharma from 2007 to 2010. Prior to Sutro, Dr. Gold was Senior
Vice President of Pharmaceutical Operations at Human Genome
Sciences from 2002 to 2006 and served as Vice President and CSO at
Covance Biotechnology Services from 1996 to 2002. Earlier in
his career, Dr. Gold held scientific and process development roles
at Khepri Pharmaceuticals, Genentech, and Genencor.
Dr. Gold holds a B.S. in Chemical Engineering from Tufts University and a M.S. and Ph.D. in
Biochemical Engineering from the Massachusetts
Institute of Technology.
About AbSci
AbSci is a global leader in protein production technologies. The
company's SoluProTM expression platform achieves
revolutionary yields of soluble and active protein products.
AbSci's unique approach accelerates drug discovery timelines,
increases manufacturing efficiencies, and drastically reduces costs
for the biopharmaceutical industry. For more information, please
visit www.abscibio.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/absci-appoints-daniel-gold-phd-to-board-of-directors-300268795.html
SOURCE AbSci